Proposal: Run WASM on CLR · Issue #13300 · dotnet/runtime
2019年8月22日 · WASM is designed to run on (JS) runtimes. So it can made to run a runtime like CLR. WASM is still low level. WASM v1 is minimal, but still manages to cover a lot. Also it may …
WAM · AzureAD/microsoft-authentication-library-for-dotnet Wiki - GitHub
For .NET Classic and .NET Core 3.x, WAM functionality is fully supported but you have to add a reference to Microsoft.Identity.Client.Desktop package, alongside MSAL, and instead of …
一、CLR基础——首先搞明白它是一个什么东西，做哪些事情，起 …
2024年11月27日 · 公共语言运行时（Common Language Runtime CLR）是一个可由多种编程语言使用的“运行时”，核心功能包括：内存管理，程序集加载，安全性、异常处理和线程同步，可 …
.NET 公共语言运行时（Common Language Runtime，CLR）
2024年11月12日 · 公共语言运行时（Common Language Runtime，简称CLR）是.NET Framework的核心组件之一，它为托管代码提供了运行环境，包括内存管理、线程管理和安全 …
Slesa/Prolog.NET: Forking Prolog.NET by R. Todd from CodePlex - GitHub
Prolog.NET is a CLI-based (ECMA International 2006) Prolog interpreter based on the Warren Abstract Machine (WAM) architecture. The original paper describing what would become …
Iopofosine I 131 Generates Efficacy Signals in Waldenström ...
2024年1月8日 · Iopofosine I 131 (CLR 131) monotherapy elicited durable responses and was associated with a tolerable safety profile in patients with heavily pretreated, multi-class …
CLOVER WaM Trial of Iopofosine I 131 Meets Primary End Point in …
2024年1月8日 · The CLOVER WaM trial (NCT02952508) evaluating treatment with iopofosine I 131 for patients with relapsed/refractory Waldenstrom’s macroglobulinemia (WM) that have …
C#.Net学习笔记——CLR核心机制 - CSDN博客
2024年1月9日 · 本文详细介绍了CLR（CommonLanguageRuntime）的基本概念，包括IL的运行环境、堆栈内存分配原理（值类型与引用类型）、拆箱装箱的性能影响、字符串的内存管理以及 …
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients …
Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.
Cellectar Biosciences Reports 83.6% Overall Response Rate for
2025年1月12日 · Cellectar Biosciences announced promising results from its Phase 2 CLOVER-WaM study of Iopofosine I 131 for relapsed/refractory Waldenstrom’s macroglobulinemia, …